Pay in 4 interest-free payments of $5.23 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
The clinical trial tested 12 weeks
The phase 2 trial enrolled 338 adults with obesity but without type 2 diabetes
Retatrutide is an investigational triple receptor agonist (GLP-1, GIP, glucagon) not yet approved by the MHRA or EMA as of 2025
Many people will also have low stomach acid, leaky gut, blood sugar imbalances, and nutrient deficiencies, all of which can further affect protein digestion and amino acid levels
Directing GLP-1 prescriptions through specific vendors or specialty pharmacies can improve pricing transparency and rebate capture
For more serious or chronic conditions, BPC-157 might require longer periods of use to show maximum results
US$ 22.47
US$ 25.95
US$ 24.86
US$ 21.32
US$ 21.58
US$ 25.65
US$ 21.82
US$ 29.45
